EGFR-ADC

EGFR-ADC (Epidermal Growth Factor Receptor-Antibody Drug Conjugate) refers to a class of targeted cancer therapeutics designed to deliver cytotoxic agents specifically to cells overexpressing EGFR. EGFR is a transmembrane protein that plays a critical role in cell growth and survival and is frequently upregulated in various solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck squamous cell carcinoma. These conjugates consist of an anti-EGFR monoclonal antibody linked to a potent cytotoxic payload, such as a microtubule inhibitor (e.g., monomethyl auristatin E or tubulysin analogs) or a DNA-damaging agent (e.g., deruxtecan). Upon binding to the receptor on the tumor cell surface, the ADC is internalized via endocytosis, and the payload is released within the lysosome to induce selective cell death. While several EGFR-ADCs have entered clinical development, managing on-target, off-tumor toxicities in healthy EGFR-expressing tissues, such as the skin and gastrointestinal tract, remains a significant challenge in their clinical advancement.

Other names

EGFR-ADCEGFR-antibody-drug conjugateanti-EGFR ADCEGFR-targeted ADC